Furthermore, treatment with bimoclomol improved MBP expression, prevented cerebellar atrophy and preserved cerebellar weights at wild-type weights in a separate cohort of Npc1−/− mice; these effects were blocked by co-administration with the Fyn kinase inhibitor, saracatinib. This evidence concerns the gene MBP and Cerebellar atrophy.